Drugs / ExPEC10V
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04306302 | Mar → Dec 2020 | — | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03819049 | Jun 2019 → Jun 2021 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ExPEC10V | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03819049 ↗ |
| Known as | JNJ-69968054 | “ExPEC10V (JNJ-69968054) is a 10-valent vaccine candidate in development for prevention of invasive extraintestinal pathogenic Escherichia coli (ExPEC) disease (IED) in adults...” NCT03819049 ↗ |
| Modality | Vaccine | “ExPEC10V (JNJ-69968054) is a 10-valent vaccine candidate in development for prevention of invasive extraintestinal pathogenic Escherichia coli (ExPEC) disease (IED) in adults...” NCT03819049 ↗ |
| Route | Intramuscular | “Participants will be randomized to receive a single intramuscular (IM) injection of low dose ExPEC10V on Day 1.” NCT03819049 ↗ |